May 10, 2019
BioSpecifics Technologies ends quarter with $4.4 million
BioSpecifics reported net income of $4.4 million for the first quarter 2019, compared to net income of $4.0 million, for the same period in 2018.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
May 9, 2019
Recipharm launches Recipharm Inhalation SolutionsTM as its end-to-end offering for inhalation products
Recipharm, the contract development and manufacturing organisation (CDMO), has launched its end-to-end inhalation offering to provide customers with a fully integrated service from early stage development through to commercial manufacturing.
May 9, 2019
Dupixent licensed in the EU for severe asthma with type 2 inflammation
The European Commission (EC) has licensed Dupixent (dupilumab), developed by Regeneron and Sanofi, for older than 12 patients as an add-on maintenance treatment for severe asthma with type 2 inflammation.
May 9, 2019
Vibalogics increases capacity with a new 200L line for virus manufacturing
GERMANY-based contract development and manufacturing organization (CDMO) Vibalogics has increased its single-use bioreactor and purification capacity with a new manufacturing line to meet increasing demand for its specialist oncolytic virus and viral vector manufacturing services.
May 9, 2019
Denali reports net loss of $39M in Q1 2019
Denali has reported net loss of $39.0 million in the first quarter 2019, compared with a net loss of $23.7 million same period last year.
May 2, 2019
Gilead net income $2B
@GileadSciences said Thursday its total revenues were $5.3 billion in 2019 compared to $5.1 billion in 2018, with net income of $2.0 billion compared to $1.5 billion in 2018.
May 2, 2019
Sanofi’s dengue vaccine approved in USA
Sanofi’s dengue vaccien Dengvaxia was approved in the USA, the company said in a press release Thursday.
May 2, 2019
Lilly presents new Emgality data
Eli Lilly will present 19 scientific abstracts for headache preventive drug Emgality (galcanezumab-gnlm) and lasmiditan at the 71st Annual Meeting of the American Academy of Neurology (AAN) taking place in Philadelphia from May 4-10, 2019.
April 25, 2019
Moleculin recruited qualified patients and started trials for two of its portfolio drugs to supplement US efforts
US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First
Patient Showing Positive Initial Treatment
April 23, 2019
Trovagene’s combo of onvansertib, venetoclax shows synergy in cell model of Venetoclax-Resistant AML
Dr. Mark Erlander, Chief Scientific Officer of Trovagene. “We believe the positive results of our preclinical study provides the scientific rationale for clinical investigation of this combination regimen and may lead to a new treatment option for these patients.”